ARCHIVES

Zeneca Buys 50% Stake In Salick, Gets Managed Care Access

This article is from The Cancer Letter archive.

Vol. 21 No. 01 | January 6, 1995

Download PDF Visit The Full Archive

Related Articles

NCI CTEP: Approved Trials For The Month of October

October 28, 2011

Economic Analysis Finds Erlotinib Marginally Cost-Effective For NSCLC

February 26, 2010

NCI Seeks Prevention Fellows.

March 9, 2001

Two Phase II Ibrutinib Studies Presented to EHA Demonstrate Efficacy as a Monotherapy

July 26, 2013

Sharp Increase In Cancer Mortality Could Bring Drastic Program Changes; All 1975 Data Needed

December 12, 1975

Economic Analyses Of New Therapies Useful In Phase III Studies, Trialists Say

July 24, 2009